Regeneron — HyperSinc

General InformationRegeneron Pharmaceuticals is a publicly-traded biotechnology company based in Tarrytown, New York, founded in 1987, with over 10,000 employees focused on inventing life-transforming biologic medicines.

Funding & FinancialsAs a public company (NASDAQ: REGN) with a market capitalization exceeding $60 billion, Regeneron has raised over $20 billion cumulatively through public markets and private financing rounds.

Leadership & TeamCEO Leonard Schleifer founded and has led Regeneron since its inception, with Chief Scientific Officer George Yancopoulos serving as co-founder and driving the company's innovative drug discovery platform.

Recent ActivityRegeneron continues advancing its pipeline across oncology, immunology, and infectious disease, with recent focus on next-generation bispecific antibodies and expanding EYLEA and DUPIXENT indications across multiple therapeutic areas.

Highlights

Total Raised

—

Latest Round

—

Stage

Public

deep-tech

Employees

1000+

Founded 1987

Headquarters

News Coverage

2 articles

Last: 1mo ago

Talent Signals

—

SEC Filings

—

News Coverage 2

Deep1mo ago

Memento launches $93M bispecific bet against retinal disease standard

Memento Medicines raised $93M to develop MMT-205, a dual-mechanism antibody challenging anti-VEGF monotherapy dominance in nAMD and DME markets worth billions annually.

Deep3mo ago

Neomorph Closes $100M Series B With First Patient Dosed

Neomorph raised $100M in Series B funding to advance NEO-811, a molecular glue degrader with a first-in-human patient already dosed in Phase 1/2 trials for renal cancer, backed by Deerfield Management and pharma giants Novo Nordisk, Biogen, and AbbVie.

Similar Companies 6

LARGO CLEAN ENERGY CORP.TREADSTONE TECHNOLOGIES, INC.QUINO ENERGY INC MUGRID ANALYTICS LONG HILL FUNDS FW1, LLC DAIRYLAND POWER COOPERATIVEPublic